פברואר 2022

הנדון: **עדכון עלון של התכשירים:**

Fortum 1 gram
Fortum 2 gram
Powder for solution for injection or infusion

מרכיבים פעילים וחוזקם:

Fortum 1 gram: ceftazidime (as pentahydrate) 1g per vial
Fortum 2 gram: ceftazidime (as pentahydrate) 2g per vial

רופא/ה נכבד/ה
רוקח/ת נכבד/ה,

חברת גלקסוסמיתקליין ישראל בע"מ (GSK) מבקשת להודיע על עדכון עלון (עלון לצרכן במתכונת עלון לרופא) של התכשירים שבנדון.

בהודעה זו מצוינים העדכונים המהותיים בלבד.
מקרא לעדכונים המסומנים:
תוספת – כתב **כחול**; ~~תוספת החמרה – כתב כחול – מסומן בצהוב מרקר~~(NA); מידע שהוסר – מסומן בקו אדום חוצה ~~XXX~~

התוויה:

Fortum is indicated for the treatment of the infections listed below in adults and children including neonates (from birth).

- Nosocomial pneumonia
- Broncho-pulmonary infections in cystic fibrosis
- Bacterial meningitis
- Chronic suppurative otitis media
- Malignant otitis externa
- Complicated urinary tract infections
- Complicated skin and soft tissue infections
- Complicated intra-abdominal infections
- Bone and joint infections
- Peritonitis associated with dialysis in patient on CAPD.

Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.
Ceftazidime may be used in the management of neutropenic patients with fever that is suspected to be due to a bacterial infection.
Ceftazidime may be used in the peri-operative prophylaxis of urinary tract infections for patients undergoing transurethral resection of the prostate (TURP).
The selection of ceftazidime should take into account its antibacterial spectrum, which is mainly restricted to aerobic Gram negative bacteria (see sections 4.4 and 5.1)
Ceftazidime should be co-administered with other antibacterial agents whenever the possible range of causive bacteria would not fall within its spectrum of activity.
Consideration should be given to official guidelines on the appropriate use of antibacterial agents.

עדכונים מהותיים שנעשו בעלון (עלון לצרכן במתכונת עלון לרופא):

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Excipient known effect
Fortum 1 gram: Each vial contains 52 mg (2.26 mmol) of sodium per vial.
Fortum 2 gram: Each vial contains 104 mg (4.52 mmol) of sodium per vial.
For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Fortum 1 gram - Powder for solution for injection or infusion
Fortum 2 gram - Powder for solution for injection or infusion
Vials containing white to cream sterile powder.

4.4 Special warnings and precautions for use

(…)

Sodium content

Important information about one of the ingredients of Fortum:

~~1 g powder for solution for injection or infusion.~~

Fortum 1 g contains 52 mg (2.26 mmol) of sodium per vial~~.~~, equivalent to 2.6% of the WHO recommended maximum daily intake of 2 g sodium for an adult.

~~2 g powder for solution for injection or infusion.~~

Fortum 2 g contains 104 mg (4.52 mmol) of sodium per vial, equivalent to 5.2% of the WHO recommended maximum daily intake of 2 g sodium for an adult.

This should be considered for patients who are on a controlled sodium diet.

(…)

PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Sodium carbonate (anhydrous sterile)

6.2. Incompatibilities

Fortum~~Ceftazidime~~ is less stable in Sodium Bicarbonate Injection than in other intravenous fluids. ~~–~~It is not recommended as a diluent.

Fortum~~Ceftazidime~~ and aminoglycosides should not be mixed in the same giving set or syringe.

Precipitation has been reported with~~when~~ vancomycin ~~has been~~ added to ceftazidime in solution. Therefore, it would be prudent to flush ~~It is recommended that~~ giving sets and intravenous lines ~~are flushed~~ between administration of these two agents.

6.3. Shelf life

The expiry date of the product is indicated on the label and packaging.

After reconstitution:

Chemical and physical in-use stability has been demonstrated for 6 days at 4°C and 9 hours at 25°C.

From a microbiological point of view, the reconstituted solution should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8°C, unless reconstitution has taken place in controlled and validated aseptic conditions.

After dilution:

Chemical and physical in-use stability has been demonstrated for 6 days at 4°C and 9 hours at 25°C.

From a microbiological point of view, the reconstituted and diluted solution should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8°C, unless reconstitution has taken place in controlled and validated aseptic conditions.

6.4. Special precautions for storage

Store~~The unconstituted product should be stored~~ below 25°~~°~~C.

Keep vials in the outer carton to protect ~~and protected~~ from light.

For storage conditions after reconstitution see section 6.3

~~Constituted solutions may be stored in the refrigerator (2 - 8°C) for up to 24 hours~~.

6.5. Nature and contents of container

Fortum 1 g powder for solution for injection or infusion is packaged in clear Ph.Eur.Type III glass 17 ml, 26 ml, 60 ml or 77 ml vial~~vials~~ with a bromobutyl rubber plug ~~closure~~ and a flip-off type~~an~~ aluminium overseal.

Packs of 1 or 5 vials

Fortum 2 g powder for solution for injection or infusion is packaged in clear Ph.Eur.Type III glass 60 ml or 77 ml vial with a bromobutyl rubber plug and a flip-off type aluminium overseal.

Pack of 1 vial.

~~Individually cartoned vials containing 1g ceftazidime (as pentahydrate) for intramuscular or intravenous use in packs of 1 or 5.~~

~~Individually cartoned vials containing 2g ceftazidime (as pentahydrate) for intravenous use in pack of 1.~~

Not all pack sizes may be marketed.

6.6. Special precautions for disposal and other handling

(…)

Instructions for constitution

See table 7 and table 8 for addition volumes and solution concentrations, which may be useful when fractional doses are required.

Table 7: Powder for Solution for Injection

Presentation ~~Vial size~~		Amount of diluent to be added (ml)	Approximate concentration (mg/ml)
1 g ~~1 g powder for solution for injection or infusion~~			
~~1 g~~	Intramuscular Intravenous bolus ~~Intravenous infusion~~	3 ml 10 ml ~~50 ml*~~	260 90 ~~20~~
2 g ~~powder for solution for injection or infusion~~			
~~2 g~~	Intravenous bolus ~~Intravenous infusion~~	10 ml ~~50 ml~~*	170 ~~40~~

~~*~~Note:

- The resulting volume of the solution of ceftazidime in reconstitution medium is increased due to the displacement factor of the drug product resulting in the listed concentrations in mg/ml presented in the above table.

Table 8: Powder for Solution for Infusion

Presentation		Amount of diluent to be added (ml)	Approximate concentration (mg/ml)
1 g			
	Intravenous infusion	50 ml*	20
2 g			
	Intravenous infusion	50 ml*	40

* Addition should be in two stages.

Note:

- The resulting volume of the solution of ceftazidime in reconstitution medium is increased due to the displacement factor of the drug product resulting in the listed concentrations in mg/ml presented in the above table.

Solutions range in colour from light yellow to amber depending on concentration, diluents and storage conditions used. -Within the stated recommendations, product potency is not adversely affected by such colour variations.

Ceftazidime at concentrations between 1 mg/ml and 40 mg/ml is compatible with:

- sodium chloride 9 mg/ml (0.9%) solution for injection
- M/6 sodium lactate injection
- compound sodium lactate injection (Hartmann's solution)
- 5% dextrose injection
- 0.225% sodium chloride and 5% dextrose injection
- 0.45% sodium chloride and 5% dextrose injection
- 0.9% sodium chloride and 5% dextrose injection
- 0.18% sodium chloride and 4% dextrose injection
- 10% dextrose injection
- Dextran 40 injection 10% in 0.9% sodium chloride injection
- Dextran 40 injection 10% in 5% dextrose injection
- Dextran 70 injection 6% in 0.9% sodium chloride injection
- Dextran 70 injection 6% in 5% dextrose injection

Ceftazidime at concentrations between 0.05 mg/ml and 0.25 mg/ml is compatible with Intra-peritoneal Dialysis Fluid (Lactate).

Fortum 1 g: Ceftazidime at concentrations detailed in Table 7 may be constituted for intramuscular use with 0.5% or 1% Lidocaine Hydrochloride Injection.

Preparation of solution for bolus injection

1. Insert the syringe needle through the vial closure and inject the recommended volume of diluent. -The vacuum may assist entry of the diluent. -Remove the syringe needle.
2. Shake to dissolve:- carbon dioxide is released and a clear solution will be obtained in about 1 to 2 minutes.
3. Invert the vial.- With the syringe plunger fully depressed, insert the needle through the vial closure and withdraw the total volume of solution into the syringe (the pressure in the vial may aid withdrawal). -Ensure that the needle remains within the solution and does not enter the head space.– The withdrawn solution may contain small bubbles of carbon dioxide; they may be disregarded.

These solutions may be given directly into the vein or introduced into the tubing of a giving set if the patient is receiving parenteral fluids. Ceftazidime is compatible with the ~~most commonly used~~ intravenous fluids listed above.

Preparation of solutions for IV infusion from ceftazidime injection in standard vial presentation (mini-bag or burette-type set):

Prepare using a total of 50 -ml ~~(for 1 g and 2 g vials)~~ of compatible diluents (listed above),~~,~~ added in TWO stages as below.

~~1.~~ Introduce the syringe needle through the vial closure and inject 10 -ml of diluent ~~for the vial~~.
~~2.~~ Withdraw the needle and shake the vial to give a clear solution.
~~3.~~ Do not insert a gas relief needle until the product has dissolved. Insert a gas relief needle through the vial closure to relieve the internal pressure.
~~4.~~ Transfer the reconstituted solution to final delivery vehicle (e.g. mini-bag or burette-type set) making up a total volume of at~~a~~ least 50 -ml, and administer by intravenous infusion over 15 to 30 min.

Note: To preserve product sterility, it is important that the gas relief needle is not inserted through the vial closure before the product has~~is~~ dissolved.~~,~~

Any residual antibiotic solution should be discarded.

For single use only.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

קיימים עדכונים נוספים. למידע נוסף יש לעיין בעלון המעודכן.
העלון נשלח לפרסום במאגר התרופות שבאתר משרד הבריאות:
https://data.health.gov.il/drugs/index.html#/byDrug
וניתן לקבלו מודפס על-ידי פניה לחברת גלקסוסמיתקליין רח' בזל 25 פתח תקוה בטלפון: 03-9297100.

בברכה,
ארינה שייקביץ
רוקחת ממונה